SCHEMBL3242722

SCHEMBL3242722

Cc1cc(C)cc(OCCC[O])c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.49
ALOX15 P16050 1/20 0.49
KDM4E B2RXH2 2/20 0.42
MAPT P10636 1/20 0.42
ALDH1A1 P00352 4/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 1/20 0.41
MAOA P21397 1/20 0.41
SLC6A2 P23975 1/20 0.41
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.38
MEN1 O00255 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12749081 0.83 TP53 (0.63) TP53ALOX15KDM4EMAPTALDH1A1
SCHEMBL5929477 0.83 TP53 (0.52) TP53ALOX15KDM4EMAPTALDH1A1
SCHEMBL4028646 0.79 TP53 (0.50) TP53ALOX15KDM4EMAPTALDH1A1
SCHEMBL1071885 0.79 TP53 (0.50) TP53ALOX15KDM4EMAPTALDH1A1
SCHEMBL2094938 0.78 ALDH1A1 (0.46) TP53ALOX15MAPTALDH1A1CYP3A4
SCHEMBL6462571 0.77 TP53 (0.53) TP53ALOX15KDM4EMAPTALDH1A1
SCHEMBL3242725 0.77 TP53 (0.62) TP53ALOX15KDM4EMAPTALDH1A1
SCHEMBL15464534 0.77 TP53 (0.49) TP53ALOX15KDM4EMAPTALDH1A1
SCHEMBL8673129 0.76 TP53 (0.47) TP53ALOX15KDM4EMAPTALDH1A1
SCHEMBL9123683 0.76 ELANE (0.49) TP53ALOX15KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2209371-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY Sarcode Corporation (US) 2010-07-28 EP claimed
US-20090155176-A1 Compositions and methods for treatment of diabetic retinopathy SARCODE CORPORATION (US) 2009-06-18 US claimed
WO-2009054914-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY SARCODE CORPORATION (US) 2009-04-30 WO claimed
US-20080108677-A1 Thioxothiazolidinone Compounds For Use As Pharmaceuticals KARYON-CTT LTD (FI) 2008-05-08 US claimed
EP-1789406-A1 THIOXOTHIAZOLIDINONE COMPOUNDS FOR USE AS PHARMACEUTICALS Karyon-CTT Ltd (FI) 2007-05-30 EP claimed
WO-2006024699-A1 THIOXOTHIAZOLIDINONE COMPOUNDS FOR USE AS PHARMACEUTICALS KARYON-CTT LTD (FI) 2006-03-09 WO claimed
US-20210338839-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY NOVARTIS AG (CH) 2021-11-04 US disclosed
EP-3797775-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY Novartis AG (CH) 2021-03-31 EP disclosed
US-10960087-B2 Compositions and methods for treatment of diabetic retinopathy NOVARTIS AG (CH) 2021-03-30 US disclosed
EP-3167886-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA NOVARTIS AG (CH) 2020-08-05 EP disclosed
EP-3167886-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA SARcode Bioscience Inc. (US) 2017-05-17 EP disclosed
EP-2209371-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY SARCODE BIOSCIENCE INC (US) 2017-01-04 EP disclosed
US-20160220702-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY SARCODE BIOSCIENCE INC. (US) 2016-08-04 US disclosed
EP-2209371-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY Sarcode Corporation (US) 2010-07-28 EP disclosed
US-20090155176-A1 Compositions and methods for treatment of diabetic retinopathy SARCODE CORPORATION (US) 2009-06-18 US disclosed
WO-2009054914-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY SARCODE CORPORATION (US) 2009-04-30 WO disclosed
US-20080108677-A1 Thioxothiazolidinone Compounds For Use As Pharmaceuticals KARYON-CTT LTD (FI) 2008-05-08 US disclosed
EP-1789406-A1 THIOXOTHIAZOLIDINONE COMPOUNDS FOR USE AS PHARMACEUTICALS Karyon-CTT Ltd (FI) 2007-05-30 EP disclosed
WO-2006024699-A1 THIOXOTHIAZOLIDINONE COMPOUNDS FOR USE AS PHARMACEUTICALS KARYON-CTT LTD (FI) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10960087-B2 Compositions and methods for treatment of diabetic retinopathy VCAM1, ITGB1, ICAM1 TP53 4320/4885ALOX15 492/4885KDM4E 2791/4885
US-20090155176-A1 Compositions and methods for treatment of diabetic retinopathy VCAM1, ITGB1, ICAM1 TP53 4320/4885ALOX15 492/4885KDM4E 2791/4885
US-20210338839-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY VCAM1, ITGB1, ICAM1 TP53 4320/4885ALOX15 492/4885KDM4E 2791/4885
US-20160220702-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY VCAM1, ITGB1, ICAM1 TP53 4320/4885ALOX15 492/4885KDM4E 2791/4885
US-20080108677-A1 Thioxothiazolidinone Compounds For Use As Pharmaceuticals ITGAM, ITGB1, ITGA1 TP53 1991/4885ALOX15 1073/4885KDM4E 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.